JustWire.io

Tue, 03.11.2026 Bayer

Bayer Summary Bayer today announced that new data from its cardiovascular, kidney and stroke portfolios will be featured at the American Heart Association Scientific Sessions in Chicago, Illinois from November 6-9, 2026. Key Facts A late-breaking oral presentation will feature data from an exploratory post-hoc analysis of the Phase 3 OCEA...

Newsfeed

Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions | Bayer AG

Bayer Shares New Post Hoc Analysis Of Self-Reported Sleep-Related Outcomes with Lynkuet® (elinzanetant) in Women with Moderate to Severe Vasomotor Symptoms at the Menopause Society Annual Meeting | Bayer AG

ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence | Bayer AG

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting | Bayer AG

Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause | Bayer AG

U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes | Bayer AG

Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States | Bayer AG

Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle | Bayer AG

MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option | Bayer AG

U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer | Bayer AG

Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs | Bayer AG

Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes | Bayer AG

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road | Bayer AG

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer | Bayer AG

BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION | Bayer AG

Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026 | Bayer AG

Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026 | Bayer AG

LYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer | Bayer AG

One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin | Bayer AG

New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters | Bayer AG

Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials | Bayer AG

Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming | Bayer AG

Bayer secures 3.0 billion euros to improve capital structure | Bayer AG

The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials | Bayer AG

Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart | Bayer AG

Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon | Bayer AG

Bayer and Iambic Collaborate to Advance Drug Discovery with AI | Bayer AG

Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada | Bayer AG

Bayer Completes Acquisition of Perfuse Therapeutics | Bayer AG

Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief | Bayer AG

Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions | Bayer AG

Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business | Bayer AG

Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth | Bayer AG

Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease | Bayer AG

Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026 | Bayer AG

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial | Bayer AG

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio | Bayer AG

Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease | Bayer AG

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | Bayer AG

U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer | Bayer AG

AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer | Bayer AG

Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement | Bayer AG

Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities | Bayer AG

Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis | Bayer AG

Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline | Bayer AG

New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing | Bayer AG

Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian | Bayer AG

XFRA: DIVIDEND/INTEREST INFORMATION - 27.04.2026 - DE000BAY0017 | Bayer AG

XETR: DIVIDEND/INTEREST INFORMATION - 27.04.2026 - DE000BAY0017 | Bayer AG

Bayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural Class | Bayer AG